Agenus (AGEN) Cash from Operations (2010 - 2026)
Agenus (AGEN) posted quarterly Cash from Operations of 35950000.0 for Q1 2026, down 40.33% year-over-year from 60249057.96 in Q1 2025, and down 116.33% quarter-over-quarter from 16618000.0 in Q4 2025.
Powered by 
Analysis
Agenus (AGEN) Cash from Operations (2010 - 2026) Analysis & Trends
Agenus' Cash from Operations history runs 17 years deep, the most recent figure standing at 35950000.0 for Q1 2026.
- In Q1 2026, Cash from Operations fell 40.33% year-over-year to 35950000.0; the TTM figure through Mar 2026 stood at 87527000.0 (up 39.94% YoY), while the FY2025 annual figure was 77195000.0, up 51.24% from the prior year.
- Cash from Operations for Q1 2026 stood at 35950000.0, down from 16618000.0 in the prior quarter.
- The five-year high for Cash from Operations was 14737000.0 in Q3 2025, with the low at 65231000.0 in Q3 2023.
- The 5-year median for Cash from Operations is 38191000.0 (2024), against an average of 39472647.06.
- The sharpest annual moves came in 2022 and 2025: Cash from Operations plunged 124.5% in 2022, then soared 72.35% in 2025.
- Agenus' Cash from Operations stood at 47338000.0 in 2022, then grew by 14.65% to 40402000.0 in 2023, then gained by 29.08% to 28652000.0 in 2024, then soared by 42.0% to 16618000.0 in 2025, then plunged by 116.33% to 35950000.0 in 2026.
- Business Quant data shows AGEN's Cash from Operations at 35950000.0 in Q1 2026, 16618000.0 in Q4 2025, and 14737000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Agenus | 342.69 Mn | 342.69 Mn | 34.52 Mn | -31.20 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -31.20 Mn |
| Mar 31, 2026 | -35.95 Mn |
| Dec 31, 2025 | -16.62 Mn |
| Sep 30, 2025 | -14.74 Mn |
| Jun 30, 2025 | -20.22 Mn |
| Mar 31, 2025 | -25.62 Mn |
| Dec 31, 2024 | -28.65 Mn |
| Sep 30, 2024 | -53.29 Mn |
| Jun 30, 2024 | -38.18 Mn |
| Mar 31, 2024 | -38.19 Mn |
| Dec 31, 2023 | -40.40 Mn |
| Sep 30, 2023 | -65.23 Mn |
| Jun 30, 2023 | -60.04 Mn |
| Mar 31, 2023 | -58.53 Mn |
| Dec 31, 2022 | -47.34 Mn |
| Sep 30, 2022 | -32.19 Mn |
| Jun 30, 2022 | -43.45 Mn |
| Mar 31, 2022 | -52.39 Mn |
| Dec 31, 2021 | -22.93 Mn |
| Sep 30, 2021 | 131.37 Mn |